- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes), Mild Cognitive Impairment
- Interventions
- Not listed
- Lead sponsor
- Novoic Limited
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Santa Ana, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 209
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- Pramlintide challenge test
- Drug
- Lead sponsor
- Boston University
- Other
- Eligibility
- 60 Years to 90 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Boston, Massachusetts • Jamaica Plain, Massachusetts
- Conditions
- Early-Onset Alzheimer Disease
- Interventions
- ALN-APP, Placebo
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 2
- States / cities
- La Jolla, California • Indianapolis, Indiana
- Conditions
- Early Alzheimer's Disease
- Interventions
- CT1812, Placebo
- Drug
- Lead sponsor
- Cognition Therapeutics
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 41 more
- Conditions
- Alzheimer Disease
- Interventions
- Donanemab, Placebo, LY3202626
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 56
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Fullerton, California + 47 more
- Conditions
- Dementia, Alzheimer Disease, Memory Loss
- Interventions
- psychoeducational skills training intervention
- Behavioral
- Lead sponsor
- Arizona State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Alzheimer Disease, Early Onset
- Interventions
- PMN310, Placebo
- Drug
- Lead sponsor
- ProMis Neurosciences, Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 22
- States / cities
- Irvine, California • Long Beach, California • Atlantis, Florida + 18 more
- Conditions
- Alzheimer Disease, Early Onset
- Interventions
- AD-35 60mg group, Placebo group
- Drug
- Lead sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 10
- States / cities
- Sacramento, California • San Diego, California • Delray Beach, Florida + 7 more
- Conditions
- Family Caregivers, Dementia, Financial Wellbeing, Financial Coaching
- Interventions
- Financial Counseling and Advocacy
- Behavioral
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 25 Years to 55 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- North Coast Medical Activadose II
- Device
- Lead sponsor
- The Mind Research Network
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD), Significant Memory Concern (SMC), Early Mild Cognitive Impairment (EMCI), Late Mild Cognitive Impairment (LMCI)
- Interventions
- Florbetapir, Flortaucipir
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 1,182 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2017
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 43 more
- Conditions
- Alzheimer Disease, Early Onset, MCI, Aging, Mild Cognitive Impairment, Neurocognitive Disorder, Cognitive Impairment, Cognitive Change
- Interventions
- physical exercise alone (PES) first, cognitive exercise alone (iCE) first, interactive Physical and Cognitive Exercise (iPACES™)
- Behavioral · Device
- Lead sponsor
- Union College, New York
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Schenectady, New York
- Conditions
- Alzheimer Disease, Healthy Aging
- Interventions
- Usability evaluation of BrightGo computerized device for cognitive therapy of individuals with early Alzheimer's Disease
- Device
- Lead sponsor
- Bright Cloud International Corp
- Industry
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- North Brunswick, New Jersey
- Conditions
- Alzheimer's Disease
- Interventions
- GSK4527226
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 9
- States / cities
- Maitland, Florida • Miami, Florida • Stuart, Florida + 6 more
- Conditions
- Alzheimer's Disease (AD)
- Interventions
- VY7523, Placebo Comparator
- Drug
- Lead sponsor
- Voyager Therapeutics
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 19
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 14 more
- Conditions
- Alzheimer's Disease
- Interventions
- Aducanumab (BIIB037), Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 1,643 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 50 more
- Conditions
- Alzheimer Disease
- Interventions
- flortaucipir F18, Brain PET Scan
- Drug · Procedure
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Down Syndrome-Associated Alzheimer's Disease (DS-AD)
- Interventions
- Mivelsiran, Placebo
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 55 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 2
- States / cities
- Maitland, Florida • Naples, Florida
- Conditions
- Alzheimer Disease
- Interventions
- Gantenerumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 7
- States / cities
- Atlantis, Florida • Maitland, Florida • Ocala, Florida + 4 more
- Conditions
- Alzheimer Disease, Early Onset
- Interventions
- Sustiva Pill
- Drug
- Lead sponsor
- Case Western Reserve University
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Beachwood, Ohio
- Conditions
- Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Moderate Dementia
- Interventions
- Emtriva Capsule, Placebo
- Drug
- Lead sponsor
- Butler Hospital
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Providence, Rhode Island
- Conditions
- Alzheimer Dementia, Alzheimer Disease, Dementia of Alzheimer Type, Mild Cognitive Impairment
- Interventions
- Levetiracetam, Placebo oral capsule
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Alzheimer Disease, Early Onset
- Interventions
- Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents, Positron Emission Tomography (PET), Amyvid, MK-6240, Dotarem, Blood draw, UR5e, Urine test
- Device · Drug · Other + 2 more
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Interventions
- E2814, Lecanemab, Matching Placebo (E2814)
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more